{"nct_id":"NCT02137343","title":"A Phase 3 Study of Rilotumumab (AMG 102) With Cisplatin and Capecitabine (CX) as First-line Therapy in Gastric Cancer","status":"TERMINATED","status_verified_date":"2016-03","start_date":"2014-07","start_date_type":null,"primary_completion_date":"2015-06","primary_completion_date_type":"ACTUAL","completion_date":"2015-06","completion_date_type":"ACTUAL","phases":["PHASE3"],"tickers":["AMGN"]}